Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
clinical decrease » clinical disease (Expand Search), linear decrease (Expand Search), clinical areas (Expand Search)
clinical case » clinical cases (Expand Search), clinical care (Expand Search), clinical course (Expand Search)
Showing 1,921 - 1,940 results of 25,426 for search '(( significant decrease decrease ) OR ( significant ((clinical decrease) OR (clinical case)) ))', query time: 0.60s Refine Results
  1. 1921
    Olfactory function test graphical summary and results.

    Olfactory function test graphical summary and results. by Myeongguk Jeong (16386165)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 1922
    Effects of BM-MSCs on different types of lung cell death in different group.

    Effects of BM-MSCs on different types of lung cell death in different group. by Chen Lu (135200)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 1923
    DDC for four anticoagulants from 2019 to 2023.

    DDC for four anticoagulants from 2019 to 2023. by Wei Luo (80175)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 1924
    A schematic representation of how BM-MSCs reduce inflammation, oxidative stress, and cell death to alleviate decompression induced acute lung injury.

    A schematic representation of how BM-MSCs reduce inflammation, oxidative stress, and cell death to alleviate decompression induced acute lung injury. by Chen Lu (135200)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 1925
    Raw Data.

    Raw Data. by Chen Lu (135200)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 1926
    Utilization of anticoagulants from 2019 to 2023.

    Utilization of anticoagulants from 2019 to 2023. by Wei Luo (80175)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 1927
    The expenditure on anticoagulants in the period of 2019-2023(million CNY).

    The expenditure on anticoagulants in the period of 2019-2023(million CNY). by Wei Luo (80175)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 1928
    Immunohistochemical staining results for OMP in olfactory bulb.

    Immunohistochemical staining results for OMP in olfactory bulb. by Myeongguk Jeong (16386165)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 1929
    From lab-to-clinic with model informed formulation development: a case study of hydroxyzine SR tablets

    From lab-to-clinic with model informed formulation development: a case study of hydroxyzine SR tablets by Aditya Murthy (9659516)

    Published 2025
    Save to List
    Saved in:
  10. 1930
    Supplementary Material for: Clinical and Genetic Insights into Congenital Generalized Lipodystrophy Type 4: A Case Report

    Supplementary Material for: Clinical and Genetic Insights into Congenital Generalized Lipodystrophy Type 4: A Case Report by figshare admin karger (2628495)

    Published 2025
    “…Introduction: Lipodystrophy syndromes (LS) represent a clinically and genetically diverse group of disorders characterised by a partial or generalised deficiency of adipose tissue. …”
    Save to List
    Saved in:
  11. 1931
    Mice subjected to chronic stress and provided with HRW exhibited a significant reduction in oxidative stress levels.

    Mice subjected to chronic stress and provided with HRW exhibited a significant reduction in oxidative stress levels. by Qi He (384033)

    Published 2025
    Save to List
    Saved in:
  12. 1932
    Mice subjected to chronic stress and provided with HRW exhibited a significant reduction in lipid peroxidation levels.

    Mice subjected to chronic stress and provided with HRW exhibited a significant reduction in lipid peroxidation levels. by Qi He (384033)

    Published 2025
    Save to List
    Saved in:
  13. 1933
    Characterization of systolic pulmonary arterial pressure (sPAP) of WT BMP9 in rats.

    Characterization of systolic pulmonary arterial pressure (sPAP) of WT BMP9 in rats. by Tobias G. Schips (21799838)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 1934
    Pharmacological characterization of WT BMP9 and A347E variant <i>in vitro</i> and <i>in vivo.</i>

    Pharmacological characterization of WT BMP9 and A347E variant <i>in vitro</i> and <i>in vivo.</i> by Tobias G. Schips (21799838)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 1935
    Summary of cell-based assay EC50 results for WT BMP9 and A347E variant.

    Summary of cell-based assay EC50 results for WT BMP9 and A347E variant. by Tobias G. Schips (21799838)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 1936
    Evaluation of chronic <i>in vivo</i> efficacy in 21 days rat MCT model in prevention mode.

    Evaluation of chronic <i>in vivo</i> efficacy in 21 days rat MCT model in prevention mode. by Tobias G. Schips (21799838)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 1937
    Hemodynamic effects of WT BMP9 in rats.

    Hemodynamic effects of WT BMP9 in rats. by Tobias G. Schips (21799838)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 1938
    Evaluation of chronic <i>in vivo</i> efficacy in 21 days rat MCT model in prevention mode.

    Evaluation of chronic <i>in vivo</i> efficacy in 21 days rat MCT model in prevention mode. by Tobias G. Schips (21799838)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 1939
    <i>In vivo</i> PK evaluation of WT BMP9 in naïve SD rats.

    <i>In vivo</i> PK evaluation of WT BMP9 in naïve SD rats. by Tobias G. Schips (21799838)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 1940
    Pharmacological characterization of WT BMP9 and A347E variant <i>in vitro</i> and <i>in vivo.</i>

    Pharmacological characterization of WT BMP9 and A347E variant <i>in vitro</i> and <i>in vivo.</i> by Tobias G. Schips (21799838)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: